Key Highlights
- Entact Bio appoints Ruben Tommasi, Ph.D., as Chief Scientific Officer.
- Dr. Tommasi brings 30 years of drug discovery leadership across multiple therapeutic areas.
- Tommasi previously served at Dunad Therapeutics and Entasis Therapeutics, driving successful clinical outcomes.
- Entact Bio focuses on precision medicines that enhance beneficial protein function via the Encompass™ platform.
Source: Business Wire
Notable Quotes
- “We’re thrilled to welcome Ruben, who brings deep expertise in drug discovery and has a proven record in successfully advancing compounds from program inception to clinical development and regulatory approval.” — Victoria Richon, Ph.D., CEO at Entact Bio
- “I was very attracted to the innovative modality Entact is developing as it holds tremendous potential to pursue new, undrugged targets believed to be beneficial against disease.” — Ruben Tommasi, Ph.D., Chief Scientific Officer at Entact Bio
SoHC's Take
The appointment of Dr. Ruben Tommasi as Chief Scientific Officer marks a pivotal moment for Entact Bio. His extensive experience in drug discovery, particularly in progressing compounds through to FDA approval, will likely accelerate the development of Entact’s innovative ENTAC™ medicines. With a proven track record across multiple therapeutic areas, Dr. Tommasi’s leadership will strengthen the company’s ability to explore novel therapeutic targets and address diseases that current treatments cannot effectively reach. This strategic move positions Entact Bio to further expand its impact on precision medicine, potentially offering new hope to patients in underserved disease areas.
Heading
Episode Details: Dental Financial Solutions Join us on this week's episode of our new Dental focused show, hosted by Jared ...
Key Highlights $11.5M Series A funding led by Construct Capital with participation from GC 1 Capital, One Way Ventures, and 2048 ...
Key Highlights Tabia Health integrates American Heart Association CarePlans into its AI-powered healthcare orchestration platform. Joins the American Heart Association Center ...
Key Highlights Heyward Donigan appointed CEO of Health Network One beginning January 1, 2025. Luis Mosquera transitions to Executive Chairman, focusing on strategic growth. Donigan ...
Key Highlights $31.5 million Series B funding led by Oak HC/FT, backed by Y Combinator, Reach Capital, and more. Programs for ...
Key Highlights Patterson Dental extends partnership with PDS Health until 2027. Agreement secures Patterson as PDS Health’s premier distributor for technology, equipment, and services. Over ...
